Milestone's stock jumps 25% on positive data for tachycardia treatment
marketwatch.com
news
2022-10-17 13:14:14

Shares of Milestone Pharmaceuticals Inc. MIST, -5.14% gained 25.4% in premarket trading on Monday after the company said its experimental treatment for paroxysmal supraventricular tachycardia met the primary endpoint in a Phase 3 study. Paroxysmal supraventricular tachycardia is a type of arrhythmia. The treatment, etripamil, is a nasal spray. Milestone said it plans to submit a new drug application for etripamil to the Food and Drug Administration in mid-2023. The company's stock is up 29.6% this year, while the broader S&P 500 SPX, -2.
